309 related articles for article (PubMed ID: 26742426)
1. Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
Noda S; Takahashi A; Hayashi T; Tanuma S; Hatakeyama M
Biochem Biophys Res Commun; 2016 Jan; 469(4):1133-9. PubMed ID: 26742426
[TBL] [Abstract][Full Text] [Related]
2. Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish.
Bonetti M; Paardekooper Overman J; Tessadori F; Noël E; Bakkers J; den Hertog J
Development; 2014 May; 141(9):1961-70. PubMed ID: 24718990
[TBL] [Abstract][Full Text] [Related]
3. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
Fragale A; Tartaglia M; Wu J; Gelb BD
Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
[TBL] [Abstract][Full Text] [Related]
4. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.
Zheng H; Yu WM; Waclaw RR; Kontaridis MI; Neel BG; Qu CK
Sci Signal; 2018 Mar; 11(522):. PubMed ID: 29559584
[TBL] [Abstract][Full Text] [Related]
5. Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11).
Qiu W; Wang X; Romanov V; Hutchinson A; Lin A; Ruzanov M; Battaile KP; Pai EF; Neel BG; Chirgadze NY
BMC Struct Biol; 2014 Mar; 14():10. PubMed ID: 24628801
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations.
Yu ZH; Zhang RY; Walls CD; Chen L; Zhang S; Wu L; Liu S; Zhang ZY
Biochemistry; 2014 Jul; 53(25):4136-51. PubMed ID: 24935154
[TBL] [Abstract][Full Text] [Related]
7. LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling.
Ishida H; Kogaki S; Narita J; Ichimori H; Nawa N; Okada Y; Takahashi K; Ozono K
Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1531-9. PubMed ID: 21803945
[TBL] [Abstract][Full Text] [Related]
8. PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice.
Paardekooper Overman J; Yi JS; Bonetti M; Soulsby M; Preisinger C; Stokes MP; Hui L; Silva JC; Overvoorde J; Giansanti P; Heck AJ; Kontaridis MI; den Hertog J; Bennett AM
Mol Cell Biol; 2014 Aug; 34(15):2874-89. PubMed ID: 24865967
[TBL] [Abstract][Full Text] [Related]
9. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.
Kontaridis MI; Swanson KD; David FS; Barford D; Neel BG
J Biol Chem; 2006 Mar; 281(10):6785-92. PubMed ID: 16377799
[TBL] [Abstract][Full Text] [Related]
10. Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes.
Martinelli S; Torreri P; Tinti M; Stella L; Bocchinfuso G; Flex E; Grottesi A; Ceccarini M; Palleschi A; Cesareni G; Castagnoli L; Petrucci TC; Gelb BD; Tartaglia M
Hum Mol Genet; 2008 Jul; 17(13):2018-29. PubMed ID: 18372317
[TBL] [Abstract][Full Text] [Related]
11. Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase.
Miura K; Wakayama Y; Tanino M; Orba Y; Sawa H; Hatakeyama M; Tanaka S; Sabe H; Mochizuki N
Oncogene; 2013 Nov; 32(45):5292-301. PubMed ID: 23318428
[TBL] [Abstract][Full Text] [Related]
12. Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase/AKT/glycogen synthase kinase 3beta signaling.
Edouard T; Combier JP; Nédélec A; Bel-Vialar S; Métrich M; Conte-Auriol F; Lyonnet S; Parfait B; Tauber M; Salles JP; Lezoualc'h F; Yart A; Raynal P
Mol Cell Biol; 2010 May; 30(10):2498-507. PubMed ID: 20308328
[TBL] [Abstract][Full Text] [Related]
13. Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations.
Yu ZH; Xu J; Walls CD; Chen L; Zhang S; Zhang R; Wu L; Wang L; Liu S; Zhang ZY
J Biol Chem; 2013 Apr; 288(15):10472-82. PubMed ID: 23457302
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.
Marin TM; Keith K; Davies B; Conner DA; Guha P; Kalaitzidis D; Wu X; Lauriol J; Wang B; Bauer M; Bronson R; Franchini KG; Neel BG; Kontaridis MI
J Clin Invest; 2011 Mar; 121(3):1026-43. PubMed ID: 21339643
[TBL] [Abstract][Full Text] [Related]
15. SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver.
Takahashi A; Tsutsumi R; Kikuchi I; Obuse C; Saito Y; Seidi A; Karisch R; Fernandez M; Cho T; Ohnishi N; Rozenblatt-Rosen O; Meyerson M; Neel BG; Hatakeyama M
Mol Cell; 2011 Jul; 43(1):45-56. PubMed ID: 21726809
[TBL] [Abstract][Full Text] [Related]
16. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
[TBL] [Abstract][Full Text] [Related]
17. LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesity.
Tajan M; Batut A; Cadoudal T; Deleruyelle S; Le Gonidec S; Saint Laurent C; Vomscheid M; Wanecq E; Tréguer K; De Rocca Serra-Nédélec A; Vinel C; Marques MA; Pozzo J; Kunduzova O; Salles JP; Tauber M; Raynal P; Cavé H; Edouard T; Valet P; Yart A
Proc Natl Acad Sci U S A; 2014 Oct; 111(42):E4494-503. PubMed ID: 25288766
[TBL] [Abstract][Full Text] [Related]
18. New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.
Schramm C; Edwards MA; Krenz M
J Biol Chem; 2013 Jun; 288(25):18335-44. PubMed ID: 23673659
[TBL] [Abstract][Full Text] [Related]
19. Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects.
Jopling C; van Geemen D; den Hertog J
PLoS Genet; 2007 Dec; 3(12):e225. PubMed ID: 18159945
[TBL] [Abstract][Full Text] [Related]
20. Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1.
Hanna N; Montagner A; Lee WH; Miteva M; Vidal M; Vidaud M; Parfait B; Raynal P
FEBS Lett; 2006 May; 580(10):2477-82. PubMed ID: 16638574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
